

Haematologica
HAEMATOL/2014/119545
Version 3

A pooled analysis of overall survival in COMFORT-I and COMFORT-II,
2 randomized phase 3 trials of ruxolitinib for the treatment of
myelofibrosis

Disclosures: A.M.V. has received has received research support from Novartis through his institution and has received personal fees for serving as a speaker to Novartis and for participation in advisory board meetings for Novartis. H.M.K. has nothing to disclose. J.-J.K. has received research support from Novartis and has received personal fees for serving as a speaker to Novartis and for participation in advisory board meetings for Novartis, Shire, and AOP Orphan. J.G. has received research support from Incyte and has received personal fees for serving on speakers' bureau for Novartis and CTI-Baxter and for participation in advisory board meetings for Novartis, Sanofi-Aventis, Gilead and CTI-Baxter. R.A.M. has nothing to disclose. N.J.S. is employed by, owns stock, and has equity ownership in Incyte Corporation. W.P. is employed by and owns stock in Incyte Corporation. V.Sandor. is employed by and owns stock in Incyte Corporation. P.G. is employed by Novartis Pharma AG. A.H. is employed by Novartis Pharma AG. V.Stalbovskaya is employed by and owns stock in Novartis Pharma AG. V.G. has received research support from Incyte Corporation and Novartis through his institution and has received personal fees for serving as a speaker to Novartis and for participation in advisory board meetings for Incyte Corporation and Novartis. C.H. has received research support from Novartis and Shire and has received personal fees from Novartis, Sanofi-Aventis, YMBioscience, Cell Therapeutics Inc., Shire and SBio. S.V. has received research support from Incyte Corporation as well as AstraZeneca, Roche, Geron, NS Pharma, Bristol-Myers Squibb, Celgene, Infinity Pharmaceutical, Gilead, Seattle Genetics, Promedior, Cell Therapeutics Inc., Galena Biopharma, and Pfizer through his institution.

Contributions: A.M.V., J.-J.K, J.G., F.C., and V.G. performed research and contributed to data collection and interpretation. H.M.K., R.A.M., C.H., and S.V. contributed to study design, data collection, and data interpretation and performed the research. N.J.S. and V. Sandor. contributed to study design and data interpretation. W.P., A.H., and V.Stalbovskaya performed statistical analyses. P.G. contributed to data interpretation. All authors were involved with drafting the manuscript and approved the final version.